Shandong Xinhua Pharmaceutical Co (HKSE:00719) Debt-to-Equity : 0.28 (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Debt-to-Equity?

Shandong Xinhua Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$562 Mil. Shandong Xinhua Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$867 Mil. Shandong Xinhua Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was HK$5,176 Mil. Shandong Xinhua Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shandong Xinhua Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

HKSE:00719' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28 Med: 0.5 Max: 0.87
Current: 0.28

During the past 13 years, the highest Debt-to-Equity Ratio of Shandong Xinhua Pharmaceutical Co was 0.87. The lowest was 0.28. And the median was 0.50.

HKSE:00719's Debt-to-Equity is ranked better than
51.89% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs HKSE:00719: 0.28

Shandong Xinhua Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Debt-to-Equity Chart

Shandong Xinhua Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.50

0.34

0.30

0.34

0.30

Shandong Xinhua Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.31	0.31	0.30	0.30	0.28

Competitive Comparison of Shandong Xinhua Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Xinhua Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Debt-to-Equity falls into.

Shandong Xinhua Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shandong Xinhua Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(610.016	+	876.094)	/	4980.089
	=	0.30

Shandong Xinhua Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(561.838	+	867.288)	/	5176.138
	=	0.28

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Shandong Xinhua Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Debt-to-Equity

Traded in Other Exchanges

XIN:Germany 000756:China

Address

No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086

Website

http://www.xhzy.com

Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines